Full Text:
<2375>
Summary: 
<1078>
Suppl. Mater.: 
CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 3725
Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer
| ||||||||||||||
Xin QI, Donghui YAN, Jiachen ZUO, Rui WANG, Jiajia CHEN. Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer[J]. Journal of Zhejiang University Science B, 2021, 22(12): 1053-1059.
@article{title="Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer",
author="Xin QI, Donghui YAN, Jiachen ZUO, Rui WANG, Jiajia CHEN",
journal="Journal of Zhejiang University Science B",
volume="22",
number="12",
pages="1053-1059",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2100412"
}
%0 Journal Article
%T Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer
%A Xin QI
%A Donghui YAN
%A Jiachen ZUO
%A Rui WANG
%A Jiajia CHEN
%J Journal of Zhejiang University SCIENCE B
%V 22
%N 12
%P 1053-1059
%@ 1673-1581
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2100412
TY - JOUR
T1 - Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer
A1 - Xin QI
A1 - Donghui YAN
A1 - Jiachen ZUO
A1 - Rui WANG
A1 - Jiajia CHEN
J0 - Journal of Zhejiang University Science B
VL - 22
IS - 12
SP - 1053
EP - 1059
%@ 1673-1581
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2100412
Abstract: colorectal cancer (CRC) is the most lethal gastrointestinal cancer in both males and females worldwide (Sung et al., 2021). Because of the high heterogeneity of tumors, robust prognostic biomarkers are urgently needed in CRC management (Koncina et al., 2020). chemokine signaling is a well-known pivotal player in immunity, inflammation, and cancer metastasis (Lacalle et al., 2017; Poeta et al., 2019; Do et al., 2020), and multiple genes involved in chemokine signaling have been demonstrated as potential prognostic biomarkers for CRC (Cabrero-De Las Heras and Martínez-Balibrea, 2018; Ottaiano et al., 2020; Yu et al., 2020). Therefore, the aim of our study was to develop a chemokine signaling-based multigene signature (CSbMgSig) that could effectively predict overall survival (OS) and therapeutic response for patients with CRC.
[1]Cabrero-de Las HerasS, Martínez-BalibreaE, 2018. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol, 24(42):4738-4749.
[2]DoHTT, LeeCH, ChoJ, 2020. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers, 12(2):287.
[3]GlimeliusB, StintzingS, MarshallJ, et al., 2021. Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev, 98:102218.
[4]IchikawaN, KamiyamaT, YokooH, et al., 2020. Preoperative chemotherapy in colorectal cancer patients with synchronous liver metastasis. Mol Clin Oncol, 12(4):374-383.
[5]KamalY, SchmitSL, HoehnHJ, et al., 2019. Transcriptomic differences between primary colorectal adenocarcinomas and distant metastases reveal metastatic colorectal cancer subtypes. Cancer Res, 79(16):4227-4241.
[6]KoncinaE, HaanS, RauhS, et al., 2020. Prognostic and predictive molecular biomarkers for colorectal cancer: updates and challenges. Cancers, 12(2):319.
[7]KurzejamskaE, SacharczukM, LandázuriN, et al., 2019. Effect of chemokine (C-C motif) ligand 7 (CCL7) and its receptor (CCR2) expression on colorectal cancer behaviors. Int J Mol Sci, 20(3):686.
[8]LacalleRA, BlancoR, Carmona-RodríguezL, et al., 2017. Chapter five‒chemokine receptor signaling and the hallmarks of cancer. Int Rev Cell Mol Biol, 331:181-244.
[9]MarisaL, de ReynièsA, DuvalA, et al., 2013. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med, 10(5):e1001453.
[10]OttaianoA, ScalaS, NormannoN, et al., 2020. Prognostic and predictive role of CXC chemokine receptor 4 in metastatic colorectal cancer patients. Appl Immunohistochem Mol Morphol, 28(10):755-760.
[11]PoetaVM, MassaraM, CapucettiA, et al., 2019. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol, 10:379.
[12]QiX, WangR, LinYX, et al., 2021. A ferroptosis-related gene signature identified as a novel prognostic biomarker for colon cancer. Front Genet, 12:692426.
[13]SungH, FerlayJ, SiegelRL, et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3):209-249.
[14]YangW, SoaresJ, GreningerP, et al., 2013. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res, 41(D1):D955-D961.
[15]YuL, YangXM, XuCC, et al., 2020. Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer. Int Immunopharmacol, 89:107077.
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>